11 sep. 2020 — SenzaGen har fått uppdraget att testa kemikalier från ett amerikanskt bolag med SenzaGens testplattform GARD har högst noggrannhet av in

SenzaGens test GARD. (Genomic Allergen Rapid Detection) är en alternativ metod för allergitester som eliminerar behovet av djurförsök. GARD bygger på det

With excellent predictivity, GARD® meets needs in several industries and helps companies develop, produce and deliver safer, ethical and more sustainable products. GARD® tests are performed in SenzaGen’s GLP-approved lab and by select partners in Europe and the US. SenzaGen has its headquarters in Lund, Sweden and a subsidiary in the US. For more information, please visit: www.senzagen.com. SenzaGen is a Swedish biotech company that provides state-of-the-art non-animal tests for assessing a substance’s allergenicity. For more information visit www.senzagen.com About GARD GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics.

Om SenzaGen AB (publ) SenzaGen gör det möjligt att ersätta djurförsök med genetiska tester i provrör för att bedöma om de kemikalier vi kommer i kontakt med i vår vardag är allergiframkallande. Det kan till exempel handla om About us. SenzaGen is a Swedish biotech company that provides state-of-the-art non-animal tests for assessing a substance’s allergenicity. The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. SenzaGen har fått uppdraget att testa kemikalier från ett amerikanskt bolag med global verksamhet inom kemikalieindustrin. Den nya ordern, med ett värde på cirka 0,4 MSEK, omfattar tester med både GARD®skin och GARD®potency. 2020-05-04 SenzaGen receives GLP approval Wed, May 27, 2020 11:44 CET. SenzaGen, which develops animal-free in vitro safety tests, has received the important GLP approval from Swedac for its laboratory and the use of its test platform GARD™.

The GARD method is an in vitro test based on a human dendritic-like cell line, a set of genes and a prediction model developed using machine learning technology. By utilizing advanced processing tools in combination with high information genomic data, SenzaGen provides a test method with a better predictive accuracy than today’s animal-based methods.

GARD[®]potency och GARD[®]skin Medical Device. Om SenzaGen AB (publ) SenzaGen gör det möjligt att ersätta djurförsök med genetiska tester i provrör för att bedöma om de kemikalier vi kommer i kontakt med i vår vardag är allergiframkallande. Det kan till exempel handla om About us. SenzaGen is a Swedish biotech company that provides state-of-the-art non-animal tests for assessing a substance’s allergenicity.

GARD ® air is the only commercially available in vitro test capable of identifying chemical respiratory sensitizers. The test is recommended for use as an R&D tool. SenzaGen provides state-of-the-art non-animal tests for assessing a substance’s allergenicity.

2, Carl Arne Krister Borrebaeck.

Genomic Allergen Rapid Detection – GARD™ – is an in vitro platform for safety assessment of chemicals. SenzaGen is a spin-off company from the University of Lund in Sweden with expertise in immunology, genomics, and machine learning.
Martin jorgensen transfermarkt

SenzaGen provides state-of-the-art non-animal tests for assessing a substance’s allergenicity. The GARD™ platform is based on gene expression analysis of stimulated in vitro models of Dendritic cells. By mimicing the initial events of the immune system in response to foreign molecular structures, SenzaGen builds predictive models that are simple, yet able to reflect a complex reality. Educational insights about GARD. When you watch our webinars, you will learn in what ways GARD can support your testing needs.

registreringsbevis bil företag
nya elementar särskola
ica smedby kalmar öppettider
sjöfart och logistik flashback
vägverket boka uppkörning
kredit marknaden

Stockopedia rates SenzaGen AB as a Speculative Sucker Stock . brokers rate Allergen Rapid Detection (GARD) sensitization test through its own laboratory

The GARD method is an in vitro test based on a human dendritic-like cell line, a set of genes and a prediction model developed using machine learning technology. By utilizing advanced processing tools in combination with high information genomic data, SenzaGen provides a test method with a better predictive accuracy than today’s animal-based methods. Två externa laboratorium kommer nu att testa GARD på flera olika kemikalier för att bekräfta att testet är reproducerbart. Processen har inletts och formell validering väntas vara klar inom ett år. För mer information.